Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue.
A new long-acting octapeptide analogue of somatostatin, Des AA1,2,4,5,12,13 D Try8 somatostatin, has been tested in 8 patients with pancreatic endocrine tumours. The analogue given subcutaneously suppressed the tumour-derived hormones in patients with insulinomas, glucagonomas, and gastrinomas for up to 24 h. The prolonged action appeared to be the result of slow release from the injection site. No side-effects were observed. Studies of long-term administration of this new peptide are now warranted.
D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D003864:Depression, Chemical; D005260:Female; D005755:Gastrins / Q000037:antagonists & inhibitors / Q000378:metabolism; D005934:Glucagon / Q000037:antagonists & inhibitors / Q000378:metabolism; D006729:Hormones, Ectopic / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007329:Insulin Antagonists; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000378:metabolism*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D005755:Gastrins; D006729:Hormones, Ectopic; D007328:Insulin; D007329:Insulin Antagonists; D013004:Somatostatin; D005934:Glucagon